Last reviewed · How we verify

Bupivacaine FNB

Pacira Pharmaceuticals, Inc · FDA-approved active Small molecule

Bupivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and conduction of nerve impulses.

Bupivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and conduction of nerve impulses. Used for Infiltration anesthesia and nerve block in adults, Interscalene brachial plexus nerve block for shoulder surgery, Femoral nerve block for knee surgery.

At a glance

Generic nameBupivacaine FNB
Also known asBupivacaine
SponsorPacira Pharmaceuticals, Inc
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaPain Management / Regional Anesthesia
PhaseFDA-approved

Mechanism of action

Bupivacaine penetrates the nerve sheath and reversibly binds to sodium channels on the inner surface of the nerve cell membrane, inhibiting sodium influx and preventing depolarization. This blocks action potential generation and propagation in sensory and motor nerves. The FNB formulation (liposomal bupivacaine) provides extended duration of action through sustained release from lipid vesicles.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: